Anatara Lifesciences Ltd (ANR.AX)
Anatara Lifesciences Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Adelaide, SA, AU. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $1.9M. Its beta of 0.70 implies it has historically moved less than the broad market.
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Anatara Lifesciences Ltd is most often compared with the following Healthcare names: